Japan· JP-4291418A1025
テムシロリムス
A temsirolimus product containing テムシロリムス, registered in Japan by ファイザー, on the national reimbursement list. The same ATC class is registered in 10 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Temsirolimus is registered in 10 of 19 countries.
Countries holding a registration under ATC L01EG01 (temsirolimus), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 5 of them publish a price we can compare per daily dose
Temsirolimus · ATC L01EG01
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Polandprice
- United Kingdom
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- テムシロリムス
- Manufacturer
- ファイザー
- Country
- Japan (JP)
- ATC code
- L01EG01
- ATC class
- Temsirolimus
- Defined daily dose
- 3.57 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
596 interactions on record for temsirolimus.
Graded by severity as the source publishes them — 168 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Temsirolimus · interactions on record
596 records
- 168 severe
- 419 moderate
- 9 minor
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EG01
Temsirolimus, as other registers publish it.
- BelgiumTemsirolimus Accord 30 mgAccord Healthcare
- FinlandToriselPfizer Europe MA EEIG
- PolandToriselPfizer Europe MA EEIG
- DenmarkToriselPfizer Europe MA EEIG
- IcelandToriselPfizer Europe MA EEIG*
- CanadaTORISELPFIZER CANADA ULC
- CzechiaTORISELPfizer Europe MA EEIG, Bruxelles
- NetherlandsTorisel 25 mg/ml, concentraat voor oplossing voor infusiePfizer Europe MA EEIG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f955f6f2-d347-4759-9c24-c681b03cef6e GET /v1/drugs/f955f6f2-d347-4759-9c24-c681b03cef6e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２５ｍｇ１ｍＬ１瓶（希釈液付）",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291418A1025",
"category": "注射薬",
"price_yen": 75259,
"generic_name": "テムシロリムス",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about temsirolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.